Clinical trials
Completed Hepatitis B, Chronic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
389 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 5 |
| 2002 | 8 |
| 2003 | 10 |
| 2004 | 12 |
| 2005 | 17 |
| 2006 | 15 |
| 2007 | 20 |
| 2008 | 21 |
| 2009 | 24 |
| 2010 | 18 |
| 2011 | 20 |
| 2012 | 19 |
| 2013 | 13 |
| 2014 | 16 |
| 2015 | 19 |
| 2016 | 13 |
| 2017 | 18 |
| 2018 | 21 |
| 2019 | 11 |
| 2020 | 20 |
| 2021 | 18 |
| 2022 | 19 |
| 2023 | 13 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 389 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 38 |
| Gilead Sciences | 28 |
| GlaxoSmithKline | 24 |
| Bristol-Myers Squibb | 22 |
| Assembly Biosciences | 12 |
| Novartis Pharmaceuticals | 11 |
| Foundation for Liver Research | 7 |
| The University of Hong Kong | 7 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 6 |
| Bukwang Pharmaceutical | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatitis B, Chronic | 389 |
| Hepatitis B | 71 |
| Hepatitis | 18 |
| Liver Cirrhosis | 11 |
| Fibrosis | 10 |
| Hepatitis, Chronic | 7 |
| Carcinoma, Hepatocellular | 6 |
| Fatty Liver | 5 |
| DNA Virus Infections | 4 |
| Liver Diseases | 4 |
Trials
Showing 26 to 50 of 389. Each trial links to its page on Pharma Observatory.
289 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.